Drug Store News10d
Samsung Bioepis, Teva ink deal for Soliris biosimilar
Samsung Bioepis and Teva have entered into a license, development and commercialization agreement for Epysqli ...
Samsung Bioepis and Teva Enter into a Strategic Partnership for Commercialization of EPYSQLI® (eculizumab-aagh) in the United States
Marks a step forward in broadening treatment options for patients with paroxysmal nocturnal hemoglobinuria (PNH),atypical hemolytic uremic ...
Teva, Samsung Bioepis enter partnership for commercialization of EPYSQLI
Pharmaceutical Industries announced that the companies have entered into a license, development and commercialization agreement for EPYSQLI, Samsung Bioepis’ biosimilar to Soliris in the United States ...
Pharm Exec11d
Teva Agrees to Strategic Partnerships with Formycon AG, Klinge Biopharma, & Samsung Bioepis
New partnerships aim to expand Teva’s biosimilar portfolio and enhance access to high-cost biologics across key markets.
The Pharma Letter14d
Samsung Bioepis and Teva link up on Soliris biosimilar in USA
South Korean biosimilars developer Samsung Bioepis and Israel’s Teva Pharmaceutical Industries have entered into a license, development and commercialization agreement for Epysqli (eculizumab-aagh), ...
Eagle-Tribune15d
Samsung Bioepis and Teva Enter into a Strategic Partnership for Commercialization of EPYSQLI®
INCHEON, Korea and TEL AVIV, Israel, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Samsung Bioepis Co., Ltd. and Teva Pharmaceutical Industries Ltd. (NYSE: and TASE: TEVA) announced today that the companies ...